Douglas Insights
Key drivers for the market’s growth include the increasing incidence of cancer, the availability of new and effective therapies, for personalised medicine.
ISLE OF MAN, ISLE OF MAN, November 17, 2022 /EINPresswire.com/ — Cancer Monoclonal Antibodies Market Size Analysis:
The market for cancer monoclonal antibodies is one of the fastest-growing in the health care business. The global cancer monoclonal antibody market was worth $ ** million in 2018 and is expected to grow at a **% CAGR to reach $ ** million by 2028. This report provides a detailed analysis of the cancer monoclonal antibodies market, including drivers, restraints, opportunities, challenges, trends, and the competitive landscape.
In addition to surgery, chemotherapy, and radiation, immunotherapy based on monoclonal antibodies is a major component of cancer treatment. During the past two decades, mAbs have been recognised as one of the most effective therapeutic approaches for both solid tumours and hematologic malignancies. Rising cancer prevalence, increasing drug approvals, and a robust pipeline are the primary factors driving market expansion. Therapies based on monoclonal antibodies that are already available or are in the works could help millions of people around the world.
Some of the key findings from the report include:
The global market for cancer monoclonal antibodies is expected to reach USD XX million by 2028, with a CAGR of XX% over the period of the forecast.
Key drivers for the market’s growth include the increasing incidence of cancer, the availability of new and effective therapies, and rising demand for personalised medicine.
However, the high cost of treatment and side effects associated with monoclonal antibody therapy are some of the major challenges faced by market players.
North America is expected to be the largest market for cancer monoclonal antibodies, followed by Europe and Asia Pacific.
COVID-19 Scenario
The ongoing COVID-19 pandemic has upturned the global economy and is having a significant impact on various industries, including the cancer monoclonal antibody market. The widespread outbreak of the virus has led to a decrease in demand for cancer monoclonal antibodies as elective surgeries and cancer treatments are postponed or cancelled due to the scarcity of hospital beds. In addition, the manufacturing and supply chain of these drugs have been disrupted due to the lockdown imposed in several countries. However, with the gradual easing of lockdown restrictions, the market is expected to recover in the coming years.
Compare and choose your best-fitting market report here: https://douglasinsights.com/cancer-monoclonal-antibodies-market
The following segments are covered in the report:
By Therapies
• Avastin;
• Herceptin;
• Keytruda;
• Opdivo;
• Darzalex;
• Perjeta;
• Others
By Application
• Breast Cancer;
• Blood Cancer;
• Lung Cancer;
• Brain Tumor;
• Colorectal Cancer;
• Cervical Cancer;
• Gastric Cancer;
• Others
By End-User
• Hospitals;
• Research Laboratories;
• Others
Regional Shares:
As of 2018, North America is estimated to have the largest market share in the global market for monoclonal antibodies against cancer. This is attributed to the presence of a large number of biopharmaceutical and biotechnology companies in the region, as well as a high level of awareness among patients about the availability of these therapeutics. In addition, government support for research and development (R&D) activities is also one of the key growth drivers in the region.
Personalization or specific data?Contact us at https://douglasinsights.com/static/contact-us
Major Players Profiled in the Market Report:
The report provides an in-depth analysis of the key players in the market, including their business overviews, product offerings, and recent developments. Some of the major players profiled in the report include Johnson & Johnson; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Co.; Merck & Co.; GlaxoSmithKline plc; Novartis AG; AstraZeneca plc; Eli Lilly and Company; AbbVie
This Report Provides Answers to Important Questions
• COVID-19 impact analysis on the global cancer monoclonal antibody industry
• What are the current market trends and dynamics in the cancer monoclonal antibodies market, and what are the valuable opportunities for emerging players?
• What is driving the market for cancer monoclonal antibodies?
• What are the key challenges to market growth?
• Which segment accounts for the fastest CAGR during the forecast period?
• Which product type segment holds a larger market share and why?
• Are low- and middle-income economies investing in the cancer monoclonal antibody market?
• Key growth pockets on the basis of regions, types, applications, and end-users
• What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America, and the Middle East and Africa?
This report’s distinct data points
• Statistics on cancer monoclonal antibodies and spending worldwide
• Recent trends across different regions in terms of the adoption of cancer monoclonal antibodies across industries
• Notable developments are going on in the industry.
• Attractive investment propositions for segments as well as geography
• Comparative scenario for all the segments for years 2018 (actual) and 2028 (forecast)
Table of Content:
1. Cancer Monoclonal Antibodies Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1. Segmentation By Geography
6.2. Segmentation By Monoclonal Antibody Therapies
6.3. Segmentation By Application
6.4. Segmentation By End User
7. Cancer Monoclonal Antibodies Market Characteristics
7.1. Market Definition
7.2. Market Segmentation By Monoclonal Antibody Therapies
7.2.1. Avastin
7.2.2. Herceptin
7.2.3. Keytruda
7.2.4. Opdivo
7.2.5. Darzalex
7.2.6. Perjeta
7.2.7. Others
7.3. Market Segmentation By Application
7.3.1. Breast Cancer
7.3.2. Blood Cancer
7.3.3. Lung Cancer
7.3.4. Brain Tumor
7.3.5. Colorectal Cancer
7.3.6. Brain Tumor
7.3.7. Cervical cancer
7.3.8. Gastric cancer
7.3.9. Others
7.4. Market Segmentation By End User
7.4.1. Hospitals
7.4.2. Research Laboratories
7.4.3. Others
8. Cancer Monoclonal Antibodies Market Trends And Strategies
8.1. Product Innovation Through Strategic Collaborations
8.2. Humanized Cancer Monoclonal Antibodies
8.3. Investment in Artificial Intelligence
8.4. Technological Advancements in Gene Sequencing and Target Gene Selection
8.5. R&D Investments
8.6. Investment in Targeted and Combination Therapy
9. Impact Of COVID-19 On The Cancer Monoclonal Antibodies Market
9.1. Introduction
9.2. Supply Chain Issues
9.3. Clinical Trial Delays
9.4. Impact On Major Players
9.5. Future Outlook
…………..Continued
*More companies can be added in Detailed Report.
Access the complete market research report here – https://douglasinsights.com/cancer-monoclonal-antibodies-market
Set a budget for a custom project and see offers from publishers all over the world- https://douglasinsights.com/projects
Our Blogs:
Major Aspects of the Global Machine Learning in the Life Sciences Market – https://douglasinsights.com/blog/major-aspects-of-the-global-machine-learning-in-the-life-sciences-market
About Douglas Insights-
Douglas insights UK limited is the first company to provide comparison of market research reports by table of content, price, ratings and number of pages. We understand the value of time. Productivity and efficiency are possible when you take prompt and assured decisions. With our advanced algorithm, filters, and comparison engine, you can compare your preferred reports simultaneously, based on publisher rating, published date, price, and list of tables. Our data portal enables you to find and review the reports from several publishers. You can evaluate numerous reports on the same screen and select the sample for your best match.
Isabella Hawke
Douglas Insights
+ +44 7624 248772
email us here
Visit us on social media:
Twitter
LinkedIn
